Lilly's Lechleiter eliminates manufacturing posts

Share this article:
Lilly CEO John Lechleiter
Lilly CEO John Lechleiter
In his first major move as CEO, Eli Lilly's John Lechleiter today announced plans to cut 500 manufacturing jobs at sites near the company's Indianapolis headquarters.

The manufacturing sites focused on production of ingredients for insulin products Humulin and Humalog and osteoporosis treatment Forteo. While most of the cuts are planned for manufacturing, some will come from R&D, Lilly said.

“For several years we have focused on strategic efforts to lower costs, increase flexibility and improve productivity across the business,” Lechleiter said in a statement. “This strategy calls for reducing investments in some areas while increasing investments in others, and the streamlining decisions announced today are an example of this.”

Lechlieter stepped into the CEO role at Lilly on April 1, replacing Sidney Taurel who retired at the end of March.

Lilly has cut its global employment, mostly through attrition, by about 12% since the middle of 2004 and now has approximately 5,500 workers.

The job cuts follow Lilly's decision last month to scrap development of its inhaled insulin device dubbed AIR. 

A late-stage trial of AIR was slated to wrap in time for NDA submission of the product in 2009.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?